

DEPARTMENT OF HEALTH & HUMAN SERVICES

#### FOR US POSTAL SERVICE DELIVERY: Office of Laboratory Animal Welfare 6700B Rockledge Drive, Suite 2500, MSC 6910 Bethesda, Maryland 20892-6910 Home Page: http://grants.nih.gov/grants/olaw/olaw.htm

November 7, 2019

### PUBLIC HEALTH SERVICE NATIONAL INSTITUTES OF HEALTH

FOR EXPRESS MAIL: Office of Laboratory Animal Welfare 6700B Rockledge Drive, Suite 2500 Bethesda, Maryland 20817 Telephone: (301) 496-7163 Facsimile: (301) 402-7065

Re: Animal Welfare Assurance A3823-01 [OLAW Case 8J]

Dr. Mary Dickinson Vice President and Dean of Research Baylor College of Medicine One Baylor Plaza, BCM335 Houston, TX 77030

Dear Dr. Dickinson,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your letter dated November 5, 2019 regarding noncompliance with the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals at Baylor College of Medicine. This letter had not been preceded by a preliminary report to OLAW.

According to the information provided, our office understands that during a semi-annual inspection, 69 rats on a PHS funded activity were found that failed to receive a secondary analgesic for tracheal surgery as described in the protocol that was approved by the Institutional Animal Care and Use Committee (IACUC). No resulting animal welfare issues were identified.

Corrective actions consisted of enhanced post-approval monitoring, and an amendment to the protocol clarifying the analgesic regimen for the procedures.

OLAW appreciates your IACUC's diligence in performing its semiannual inspection responsibilities and the institution's corrective measures as described in this report. Efforts such as this help characterize the extent and nature of programmatic issues and serve as a critical step in the development of comprehensive, institution-wide corrective actions. We look forward to a description of your progress to this end in your next report under your institution's enhanced reporting schedule. Please note that reports of noncompliance to OLAW should include dates of occurrence when describing the incident. Please include this information in future submissions. Regarding this specific instance of non-compliance, we appreciate having been informed of this matter and at this time find no cause for further action by this office.

Sincerely,

(b) (6)

Nicolette Petervary, VMD, DACAW Animal Welfare Policy Specialist Office of Laboratory Animal Welfare

CC: IACUC Contact

## A3823-8J no open case

#### OFFICE OF RESEARCH

One Baylor Plaza, BCM310 Houston, Texas 77030-3411

> (713) 798 - 6966 (713) 798 - 2721 FAX mdickins@bcm.edu

# Baylor College of Medicine

### CONFIDENTIAL

November 5, 2019

Brent Morse, DVM, DACLAM Director, Division of Compliance Oversight Office of Laboratory Animal Welfare National Institutes of Health olawdco@mail.nih.gov

RE: Assurance #D16-00475

Dear Dr. Morse,

As Institutional Official for Baylor College of Medicine (BCM), I have the duty to inform you of our Institutional Animal Care and Use Committee's (IACUC) recent finding in animal research after an assessment of the following protocol:

Protocol: AN-5366: The Role of Gut Microbiome in Obstructive Sleep Apnea Induced Hypertension Species: Rat Funding Sources: National Institutes of Health (NIH) R01-HL134838 and Non-PHS funding

For this investigator's first incident of this nature, the IACUC determined that the following finding constituted serious

### Experimental Process<sup>II, III, IV</sup>

noncompliance<sup>i</sup> with the federal regulations:

During a semi-annual inspection, it was discovered that 69 rats underwent tracheal surgery as described in the approved protocol, however, a secondary analgesic was not administered according to the approved protocol. All rats were observed daily and weighed weekly to ensure that they were healthy. There were no complications observed, and all rats recovered without incident.

### **Corrective Actions:**

- 1. A Post Approval Monitoring (PAM) will be conducted within the next six months.
- 2. The protocol was amended to more clearly describe the analgesic regime for the various procedures indicated.

<sup>&</sup>lt;sup>1</sup> PHS Policy IV.F.3.a: "The IACUC, through the Institutional Official, shall promptly provide OLAW with a full explanation of the circumstances and actions taken with respect to: a. any serious or continuing noncompliance with this Policy;"

<sup>&</sup>lt;sup>ii</sup> The GUIDE, 8<sup>th</sup> Ed. p115: "Successful surgical outcomes require appropriate attention to presurgical planning, personnel training, anesthesia, aseptic and surgical technique, assessment of animal well-being, appropriate use of analgesics, and animal physiologic status during all phases of a protocol involving surgery and postoperative care."

<sup>&</sup>lt;sup>iii</sup> The GUIDE, 8<sup>th</sup> Ed. p115: "Researchers conducting surgical procedures must have appropriate training to ensure that good surgical technique is practiced – that is, asepsis, gentle tissue handling, minimal dissection of tissue, appropriate use of instruments, effective hemostasis, and correct use of suture materials and patterns."

<sup>&</sup>lt;sup>iv</sup> PHS Policy IV.B.6: "The IACUC shall with respect to PHS-conducted or supported activities "review and approve, require modifications in (to secure approval), or withhold approval of those components of PHS-conducted or supported activities related to the care and use of animals...""

This finding of non-compliance does not appear to pose any potential or actual effect on cost related to this PHS supported research.

This notification will also be sent to AAALAC International, the National Institutes of Health and the non-PHS funding source according to the terms and conditions of the award.

Please do not hesitate to contact me if you have any questions.

Sincerely,

(b) (6)

Mary Dickinson, PhD Vice President and Dean of Research Institutional Official Baylor College of Medicine

cc: Principal Investigator Department Chair Research Compliance Services files

Page 2 of 2

### Morse, Brent (NIH/OD) [E]

From: Sent: To: Cc:	OLAW Division of Compliance Oversight (NIH/OD) Tuesday, November 05, 2019 3:57 PM (b) (6) OLAW Division of Compliance Oversight (NIH/OD) (b) (6)
Subject:	RE: OLAW Report - Assurance D16-0475
Thank you for providing these rep	(b) (6) We will send official responses soon. Best regards, Brent Morse
Brent C. Morse, DVM, DACLAM	
Director	
Division of Compliance Oversight Office of Laboratory Animal Welfa National Institutes of Health	are

Please note that this message and any of its attachments are intended for the named recipient(s) only and may contain confidential, protected or privileged information that should not be distributed to unauthorized individuals. If you have received this message in error, please contact the sender.

Sents Tuesday, Nevershan OF, 2010 2:04 DM	
Sent: Tuesday, November 05, 2019 3:04 PM	
To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov></olawdco@od.nih.gov>	
Cc:	(b) (6)
Subject: OLAW Report - Assurance D16-0475	

Dear Dr. Morse,

Please find attached notification of an adverse event as determined by our IACUC, and sent on behalf of Dr. Mary Dickinson, Institutional Official. Please feel free to contact me if you have any questions.

Thank you, (७) (б)

(ხ) (б)